The aim of this clinical study is to evaluate the efficacy and tolerability of probiotics on atrial fibrillation recurrence.
Assessment of AF recurrence: Early AF recurrence is defined as relapse into AF within 1 week following successful cardioversion and AF recurrence through the study's 12-week follow-up. Patients and Methods Design: Prospective, randomized, open label, controlled clinical trial Patients: A total of 56 AF patients undergoing cardioversion will be randomly enrolled into one of 2 arms: 1. Group 1 (Control group) (n=28): AF patients undergoing cardioversion who will receive the standard of care 2. Group 2 (Probiotic group) (n = 28): AF patients undergoing cardioversion who will receive the standard of care in addition to probiotics DAILY orally administered (Probiotics 25 billion) after cardioversion for 12 weeks. Groups (1 \& 2) will be subjected to cardioversion on admission according to standard protocols and criteria.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
56
Drug: The standard of care for AF management directly following cardioversion Include anticoagulant therapy for at least 4 weeks, rate control therapy, rhythm control therapy, or both as per clinical and guideline decisions.
Probiotics at a of dose 25 billion / 1 capsule will be orally administered daily for 12 weeks
Ain Shams University's Hospital
Cairo, Egypt
Atrial Fibrillation Recurrence
Time frame: 7 days
Atrial Fibrillation Recurrence
Time frame: 12 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.